ASX Announcement

FY26 Annual Report and Key Financial Results

Melbourne, Australia; 26 August 2026: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company advancing dendrimer technology from the lab to the patient, today presents its Annual Report and full-year financial results for the year ended 30 June 2026.

Key Financial Results

- Ended FY26 with a cash balance of $11.0 million. After year-end, raised net proceeds of $30 million through a widely supported Entitlement Offer, strengthening Starpharma's cash position and extending its funding runway into FY28.

- FY26 revenue increased 145% to $12.0 million (FY25: $4.9 million), driven primarily by the $8.3 million upfront payment from the Genentech licence agreement. Revenue also included product sales, royalties, and other licence and research revenue.

- FY26 reported loss improved by 25% to $7.5 million (FY25: $10.0 million). The company continued to invest in its DEP® pipeline, including advancing the DEP® HER2-Lutetium radiopharmaceutical asset and other early-stage next-generation DEP® programs. Research and product development expenditure was $11.1 million (FY25: $8.4 million), net of the Australian Government's R&D tax incentive.

Starpharma's Chief Executive Officer, Cheryl Maley, commented:

"During FY26, we significantly advanced our lead radiopharmaceutical asset, DEP® HER2-Lutetium, executed new strategic partnerships and strengthened existing ones, and further validated the broad potential of DEP® with a focus on targeted oncology treatments. We thank our shareholders for their continued support throughout the year. Our focus remains on building long-term shareholder value through the development of a pipeline of targeted oncology therapies enabled by our DEP® technology. The team is committed to executing on the milestones ahead and translating our scientific and commercial progress into meaningful outcomes for patients and shareholders."

About Starpharma

Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.

Starpharma's portfolio of dendrimer-based products includes clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.

For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn.

Investor & Media Relations
Gabriella Hold
gaby@thecapitalnetwork.com.au

Starpharma Holdings Limited
Cheryl Maley, Chief Executive Officer
Justin Cahill, Chief Financial and Operations Officer and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford VIC 3067

Disclosure
This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas.

Forward-Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.